9 completed. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
| Phase 2 | 4 | Completed 4 |
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration OTX-TKI/Sham, Aflibercept/Sham - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Ocular Therapeutix, Inc. | 21 | 2021-07-28 | 2024-01-26 |
| Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD Eylea, ALT-L9 - Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Alteogen, Inc. | 28 | 2020-02-05 | 2022-01-20 |
| A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema Aflibercept, OPT-302, Sham intravitreal injection - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Opthea Limited | 153 | 2018-01-16 | 2025-04-22 |
| Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration Aflibercept - Neovascular Macular Degeneration | Phase 1 | Completed | University of Nebraska | 5 | 2014-09-05 | 2023-09-06 |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Sapanisertib, Ziv-Aflibercept - Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 83 | 2014-06-18 | 2025-10-20 |
| Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery Aflibercept, Sham - Diabetic Retinopathy | Phase 1 / Phase 2 | Completed | Rishi Singh | 30 | 2013-12-01 | 2020-05-22 |
| Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration Ranibizumab 0.5mg, Aflibercept 2.0mg - Neovascular Age-Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Arshad Khanani | 100 | 2013-09-01 | 2016-03-03 |
| Intravitreal Aflibercept Injection for Radiation Retinopathy Aflibercept every 2 months, Aflibercept monthly - Radiation Retinopathy, Macular Edema | Phase 1 | Completed | Washington University School of Medicine | 9 | 2012-11-01 | 2019-04-25 |
| Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF Blood Sample Collection, Aflibercept, Bevacizumab - Age-related Macular Degeneration, Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | California Retina Consultants | 56 | 2012-03-01 | 2016-05-19 |
Macular Degeneration (2) · Adenoma, Islet Cell (1) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Fibrolamellar hepatocellular carcinoma (1) · Macular Edema (1) · Neoplasm Metastasis (1) · Neovascularization, Pathologic (1) · Ovarian Neoplasms (1) · Retinal Diseases (1) · Retinal Vein Occlusion (1) · Wet Macular Degeneration (1)
Alteogen, Inc. (1) · Arshad Khanani (1) · California Retina Consultants (1) · National Cancer Institute (NCI) (1) · Ocular Therapeutix, Inc. (1) · Opthea Limited (1) · Rishi Singh (1) · University of Nebraska (1) · Washington University School of Medicine (1)
United States (7) · Australia (1) · Israel (1) · Latvia (1) · South Korea (1)
Arshad M Khanani, MD (1) · Aung Naing (1) · Diana V Do, MD (1) · Melvin D Rabena, BS (1) · Prabakar K Rao, MD (1) · Rishi Singh, M.D. (1) · Robert L Avery, MD (1)
P30CA016672 (1), U01CA062461 (1), UM1CA186688 (1)